In The News

February 18, 2021
Harmonized case report forms for clinical trials on a broad range of immunotherapies (including monoclonals, CAR-T cell therapies and T-cell engagers) should be used to better track the rates of…
February 18, 2021
YORBA LINDA, Calif., Feb. 18, 2021 /PRNewswire/ -- The Richard Nixon Foundation will host a two-day commemoration of the 1971 National Cancer Act at the Richard Nixon Presidential Library and Museum…
February 18, 2021
The identification of oncogenic driver mutations in non–small cell lung cancer to inform targeted therapy selection is the bedrock of clinical practice in this disease, with current estimates…
February 16, 2021
Executive Summary Oncology Center of Excellence program will use the Evidence Accelerator to examine COVID’s impact on treatment initiation, regimen selection and therapeutic utilization, potential…
February 16, 2021
Since joining the field of cancer research almost two decades ago, I’ve seen tremendous advances made as we’ve learned more about the disease and identified better ways to approach it. But how do we…
February 11, 2021
Characterizing cytokine release syndrome (CRS) will be key to ensuring broader uptake of advanced cell and gene therapies in the field of immuno-oncology, agreed authors of a newly issued white paper…
February 11, 2021
Acting FDA Commissioner Janet Woodcock has picked up a powerful endorsement in a public campaign for President Joe Biden to delete the “acting” part of her title. Nobel laureate James Allison and…
February 9, 2021
Abstract Purpose: Performance status (PS) is one of the most common eligibility criteria. Many trials are limited to patients with high-functioning PS, resulting in important differences between…
February 9, 2021
Executive Summary Applying the expedited pathway in the context of a preliminary benefit/risk assessment, rather than focusing solely on predictive surrogate or intermediate clinical endpoints,…
February 9, 2021
Cancer patients who are between treatments or are taking medications for other conditions wouldn’t automatically be left out of clinical trials under a proposal by advocacy groups to broaden the…